Glezen W Paul
Department of Molecular Virology & Microbiology, Baylor College of Medicine, One Baylor Plaza, Mail Stop BCM-280, Houston, TX 77030-3498, USA.
Expert Rev Vaccines. 2004 Apr;3(2):131-9. doi: 10.1586/14760584.3.2.131.
The recently licensed cold-adapted, live attenuated influenza vaccine (CAIV-T, FluMist, MedImmune Vaccines Inc.) has the potential to enhance control of epidemic influenza. The intranasal vaccine has proven safety and efficacy. Regulatory constraints and cost of CAIV-T have hampered the introduction of the vaccine in the first year. Unwarranted concern about possible transmission of the virus from vaccine recipients to immunocompromised patients limited use in healthcare personnel. The intense influenza A(H3N2) epidemic of 2003-2004 has underscored the necessity of supplementing current efforts to control influenza. Over 120 deaths have been documented in children - the majority of which have been previously healthy. Use of CAIV-T in children will not only decrease the risk of serious disease, but also dampen the spread of the virus in the community and reduce exposure of patients who are at high risk of complications and death.
最近获得许可的冷适应减毒活流感疫苗（CAIV-T，FluMist，MedImmune疫苗公司）有增强对流行性感冒控制的潜力。鼻内疫苗已证实具有安全性和有效性。CAIV-T的监管限制和成本在第一年阻碍了该疫苗的推广。对疫苗接种者可能将病毒传播给免疫功能低下患者的无端担忧限制了其在医护人员中的使用。2003 - 2004年甲型（H3N2）流感的严重流行凸显了补充当前流感控制措施的必要性。已有超过120名儿童死亡记录——其中大多数此前身体健康。在儿童中使用CAIV-T不仅会降低患重病的风险，还会抑制病毒在社区中的传播，并减少并发症和死亡高风险患者的暴露。
